Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden

Annals of the Rheumatic Diseases

Volumn 78, Issue 3, 2019, Pages 320-327

  Grøn, Kathrine Lederballe ^a,b   Arkema, Elizabeth V ^c   Glintborg, Bente ^a,d   Mehnert, Frank ^e   Østergaard, Mikkel ^a,b   Dreyer, Lene ^f   Nørgaard, Mette ^e   Krogh, Niels Steen ^g   Askling, Johan ^c   Hetland, Merete Lund ^a,b  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c KAROLINSKA INSTITUTE   (Sweden)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f AALBORG UNIVERSITY HOSPITAL   (Denmark)

^g Zitelab Aps   (Denmark)

Author keywords

DMARDs (biologic); epidemiology; infections; rheumatoid Arthritis; treatment

Indexed keywords

ABATACEPT; C REACTIVE PROTEIN; RITUXIMAB; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGE; AGED; ARTICLE; COHORT ANALYSIS; CONFOUNDING VARIABLE; DENMARK; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE REGISTRY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION RISK; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SWEDEN; TREATMENT DURATION; TREATMENT RESPONSE; INFECTION; POISSON DISTRIBUTION; REGISTER; REGRESSION ANALYSIS;

ABATACEPT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DENMARK; FEMALE; HUMANS; INFECTION; MALE; POISSON DISTRIBUTION; REGISTRIES; REGRESSION ANALYSIS; RISK FACTORS; RITUXIMAB; SWEDEN;

EID: 85059697859     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2018-214326     Document Type: Article

References (34)

1. Nam JL, Takase-Minegishi K, Ramiro S, et al. Efficacy of biological disease-modifying antirheumatic drugs: A systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2017;76:1113-36.
2. Rein P, Mueller RB. Treatment with biologicals in rheumatoid arthritis: An overview. Rheumatol Ther 2017;4:247-61.
3. Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: A systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2017;76:1101-36.
4. Zink A, Askling J, Dixon WG, et al. European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis 2009;68:1240-6.
5. Vashisht P, Sayles H, Cannella AC, et al. Generalizability of patients with rheumatoid arthritis in biologic agent clinical trials. Arthritis Care Res 2016;68:1478-88.
6. Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British society for rheumatology biologics register with special emphasis on risks in the elderly. Rheumatology 2011;50:124-31.
7. Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:1125-33.
8. S ingh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: A systematic review and metaanalysis. The Lancet 2015;386:258-65.
9. Curtis JR, Yang S, Patkar NM, et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res 2014;66:990-7.
10. L ahiri M, Dixon WG. Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis. Best Pract Res Clin Rheumatol 2015;29:290-305.
11. A altonen KJ, Joensuu JT, Virkki L, et al. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy. J Rheumatol 2015;42:372-8.
12. Johnston SS, Turpcu A, Shi N, et al. Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis. Semin Arthritis Rheum 2013;43:39-47.
13. S akai R, Cho SK, Nanki T, et al. Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. Arthritis Res Ther 2015;17:74.
14. Yun H, Xie F, Delzell E, et al. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in medicare. Arthritis Rheumatol 2016;68:56-66.
15. Rutherford AI, Subesinghe S, Hyrich KL, et al. Serious infection across biologictreated patients with rheumatoid arthritis: results from the British society for rheumatology biologics register for rheumatoid arthritis. Ann Rheum Dis 2018;77:annrheumdis-2017-212825-2010.
16. Psaty BM, Koepsell TD, Lin D, et al. Assessment and control for confounding by indication in observational studies. Journal of the American Geriatrics Society 1999;47:749-54.
17. I bfelt EH, Jensen DV, Hetland ML. The Danish nationwide clinical register for patients with rheumatoid arthritis: DANBIO. Clin Epidemiol 2016;8:737-42.
18. DANBIO. 2016. Available: https:// danbio-online. dk/ formidling/ DANBIOrsapport2016. pdf
19. E riksson JK, Askling J, Arkema EV. The Swedish rheumatology quality register: optimisation of rheumatic disease assessments using register-enriched data. Clin Exp Rheumatol 2014;32-S-147-9.
20. L ynge E, Sandegaard JL, Rebolj M. The dDanish national patient register. Scandinavian Journal of Public Health 2011;39:30-3.
21. Johannesdottir SA, Horváth-Puhó E, Ehrenstein V, et al. Existing data sources for clinical epidemiology: The danish national database of reimbursed prescriptions. Clin Epidemiol 2012;4:303-13.
22. L udvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011;11:450.
23. Registry T. 2018. Available: http://www. socialstyrelsen. se/ register/ halsodataregister/ patientregistret/ inenglish
24. S almon JH, Gottenberg JE, Ravaud P, et al. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry. Ann Rheum Dis 2016;75:1108-13.
25. S trangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient Ann Rheum Dis 2011;70:1914-20.
26. L isting J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology 2013;52:53-61.
27. Widdifield J, Bernatsky S, Paterson JM, et al. Serious infections in a populationbased cohort of 86, 039 seniors with rheumatoid arthritis. Arthritis Care Res 2013;65:353-61.
28. A skling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1339-44.
29. S hrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: A primer for physicians. J Gen Intern Med 2011;26:546-50.
30. van Dartel SAA, Fransen J, Kievit W, et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 2013;72:895-900.
31. S trand V, Ahadieh S, French J, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Research & Therapy 2015;17:362.
32. Zink A, Manger B, Kaufmann J, et al. Evaluation of the RABBIT risk score for serious infections. Ann Rheum Dis 2014;73:1673-6.
33. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: Associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006;54:628-34.
34. Greenberg JD, Reed G, Kremer JM, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010;69:380-6.